Pharmafile Logo
Pharmafocus logo
Advanced Search

Afrezza

Showing 8 posts of 8 posts found.

Arzerra

Arzerra approved by US FDA for leukaemia

January 20, 2016
Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application

The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …

News
afrezza_insulin

Sanofi abandons MannKind’s failed inhalable insulin

January 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin

Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …

News
Sanofi image

Sanofi sees FDA approval for diabetes drug

February 26, 2015
Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4

US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …

News
affrezza image

Sanofi’s inhalable insulin goes on sale in US

February 3, 2015
Sales and Marketing Afrezza, FDA, Mannkind, Sanofi, US, apidra, diabetes, insulin, type 1, type 2

Sanofi has launched its inhalable insulin Afrezza in the US to control blood sugar in people with type 1 and …

News
afrezza image

Sanofi signs $925 million inhaled insulin deal

August 13, 2014
Sales and Marketing Afrezza, French, Sanofi, diabetes, fad, insulin

Sanofi could pay out as much as $925 million for global rights to the world’s only approved inhaled insulin just …

News
Affreza image

FDA ‘yes’ to inhaled insulin

June 30, 2014
Manufacturing and Production, Sales and Marketing Afrezza, FDA, Mannkind, diabetes, insulin human

The FDA has approved the first ‘ultra-rapid-acting’ mealtime insulin therapy available in the US, to improve glycemic control in both …

News
Afrezza image

Inhaled insulin one step closer to approval

April 3, 2014
Sales and Marketing Afrezza, FDA, Mannkind, diabetes, type 1, type 2

After a rocky few years MannKind’s inhaled insulin Afrezza finally looks to be on the path to approval in the …

News
manufacturing_compounding

Mannkind’s inhaled insulin Afrezza edges closer to market

August 19, 2013
Research and Development, Sales and Marketing Afrezza, Exubera, Mannkind, inhaled insulin

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024